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The  extract  from  horse  chestnut  seeds  (Aesculus  hippocastanum  L., Sapindaceae),  standardised  for the
content  of aescin,  is used  as  the  treatment  for  chronic  venous  insufﬁciency.  It  has  anti-inﬂammatory  and
anti-oedematous  properties  and  indicates  a  positive  effect  on the venous  tone, rheological  properties,
and  blood  coagulability.  The  mechanism  of  horse  chestnut  seed  extract/aescin  activity  was  proposed  on
the basis  of in vitro  and in  vivo  studies,  and  its effectiveness  was  documented  with  numerous  randomised
clinical  trials.  The  results  of  the  studies  have  proven  that  horse  chestnut  seed  extract  not  only  signiﬁcantly
improves  subjective  symptoms  in  patients  with  chronic  venous  insufﬁciency  like calf  spasm,  leg pain,
pruritus,  fatigue,  but  it  also  reduced  leg  volume,  the  ankle  and  calf  circumference.  The  preparations  con-
taining  horse  chestnut  seed  extract  are  very  popular  and  they  have  similar  effectiveness  as compression
therapy  and  a preparation  with  O-(-hydroxyethyl)-rutosides.  Moreover,  horse  chestnut  seed  extract
has  been  proven  to be  safe and  very  well  tolerated.  The  study  was  to present  the  results  of  the  studies
that  have  been  conducted  so  far  and  that  have  conﬁrmed  the  effectiveness  of  use  of horse  chestnut  seed
extract  or aescin  as  the  treatment  for chronic  venous  insufﬁciency.
©  2015 Sociedade  Brasileira  de  Farmacognosia.  Published  by Elsevier  Editora  Ltda.  All  rights  reserved.ntroduction
Chronic venous insufﬁciency (CVI) is a disorder affecting
pproximately 25% of the European community, women in par-
icular (Piechal et al., 2005). CVI is caused by inborn or acquired
nomalies in the functioning of the venous system, resulting from
rimary defects in a vein wall and valve structure as well as insuf-
ciency thereof, and by factors inﬂuencing the weakened tension
nd structure thereof, such as hormonal changes, pregnancy, obe-
ity, limited activity, working in a sitting or standing position, and
ral contraceptives (Sudoł-Szopin´ska et al., 2006). As a result of the
eakened vascular tension and structure, blood congestion, vascu-
ar bed overﬂow, and hypoxia occur; in consequence, mitochondrial
xidative phosphorylation is inhibited, and the content of adeno-
ine triphosphate (ATP) is lowered. A decrease in ATP content in
ndothelium cells induces a series of cellular modiﬁcations, such
s an increase in cytosolic calcium concentration, the release of
nﬂammatory mediators, such as prostaglandins (Michiels et al.,
993), and the platelet-activating factor (PAF) (Arnould et al.,
993) which result in the recruitment, activation and adhesion of
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102-695X/© 2015 Sociedade Brasileira de Farmacognosia. Published by Elsevier Editorapolymorphonuclear neutrophils (Arnould et al., 1996). Leukocytes
adhering to the vascular wall release phospholipase A2 respon-
sible for production of inﬂammation precursors, toxic oxidative
metabolites, and lysosomal enzymes (elastase, collagenase). They
also lead to the increased activity of hyaluronidase that degrades
hyaluronic acid, the major constituent of capillary endothelium.
The increased activity of other enzymes being components of vas-
cular walls, i.e.  -N-acetylglucosaminidase, -glucuronidase and
arylosulphatase, responsible for degradation of proteoglycans, has
also been observed in chronic venous insufﬁciency. Degradation
of hyaluronic acid and proteoglicans results in violation of the
integrity of blood vessel walls, increased capillary permeability,
and fragility (ESCOP, 2003). In the course of an inﬂammatory reac-
tion, histamine and serotonin – the enzymes affecting the increase
in capillary permeability – are released, too. The effect of the
above-mentioned processes is migration of leukocytes outside the
vascular walls, exacerbation of the inﬂammation, occurrence of
oedema, and pathological changes in veins (Fig. 1).
Medicines of plant origin play a signiﬁcant role in the pharma-
cological treatment of CVI. The most popular ones include the horse
chestnut seed extract or aescin isolated from it and ﬂavonoids:
diosmin, hesperidin, rutin, and its derivative – troxerutin.
The aim of the study was to present the results of the stud-
ies that have been conducted so far and that have conﬁrmed the
 Ltda. All rights reserved.
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Fig. 1. Mechanisms of HCSE/aescin activity in chro
ffectiveness of use of horse chestnut seed extract (HCSE) or aescin
s the treatment for CVI.
aterial and methods
nclusion and exclusion criteria
Only randomised, controlled trials testing the efﬁcacy of oral
reparations containing HCSE as the only active component (a
ono-preparation) with the placebo or reference therapy were
ncluded. Trials assessing HCSE as one of several active components
n a combination preparation or as a part of the combination treat-
ent were excluded. In case of preparations used externally, due to
 lack of mono-preparations, the combinations preparations were
lso included. In all the trials the extract was standardised to aescin.
The studies included if participants were patients with CVI
internal use), and CVI, SVT, and foot ulcers as a result of diabetes
omplications (external use). The studies using clinical outcome
easures were included, whereas the studies focusing exclusively
n physiological parameters were excluded.
The following electronic English databases were searched: Ovid
edline, Pubmed and The Cochrane Library, from 1976 up to
ecember 2014. They were searched by title and abstract using
he following search terms: Aesculus hippocastanum,  Hippocastani
emen, horse chestnut seeds, aescin, HCSE, CVI. Hand searches were
lso conducted for publications not stored in the databases (e.g.
ebpages).
Reference lists of all the articles were searched for further pub-
ications. For the selection of the manuscripts, two independent
nvestigators (MDM,  ESS) ﬁrst assessed all the titles and abstracts
nd then carried out full text analyses of the publications, against
redeﬁned inclusion criteria.
Nineteen trials met  the above-mentioned inclusion criteria. Of
hese, nine were placebo-controlled; two compared HCSE against
he reference treatment with compression stockings and the
lacebo (Diehm et al., 1996; Diehm and Schmidt, 2001); four were
ontrolled against reference medication with O--hydroxyethyl
utosides (HR) (Erdlen, 1989; Kalbﬂeisch and Pfalzgraf, 1989; Erler,
991; Rehn et al., 1996), and one was controlled against medication
ith pycnogenol (Koch, 2002). Three trials related to preparations
sed externally were randomised, but their efﬁcacy was not com-
ared with the placebo.rgment
nous insufﬁciency. Modiﬁed based on Sirtori (2001).
Chemical constituents
Horse chestnut seeds are rich in saponins (3–5%), over thirty of
which have been isolated and identiﬁed. The main compound is
aescin – a mixture of acylated triterpene glycosides. Three frac-
tions of aescin, denoted as crypto-, -, and -aescin have been
described in the literature. Cryptoaescin contains C-28-O-acetyl
saponins, and -aescin contains C-22-O-acetyl saponins, whereas
-aescin is a mixture of crypto- and -aescin. -Aescin (mainly
made up of aescin Ia (1) and aescin Ib (2)) is the major active com-
ponent of extracts from horse chestnut seeds, whereas -aescin
(made up mainly of isoaescin Ia (5) and isoaescin Ib (6)) is less bioac-
tive (ESCOP, 2003). Horse chestnut seeds also contain ﬂavonoids:
quercetin and kaempferol derivatives, proanthocyanidins, sterols,
and signiﬁcant amounts of starch (ESCOP, 2003).
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The effectiveness of HCSE and aescin as the treatment for chronic
enous insufﬁciency results from the anti-oedematous and anti-
nﬂammatory activity as well as their inﬂuence on the tension of
lood vessel walls. The biological activity of both horse chestnut
eed extract (HCSE) standardised for the content of aescin and iso-
ated aescin has been conﬁrmed by numerous in vitro, in vivo, and
he clinical studies (Pittler and Ernst, 2012). The results from the
tudies have been presented below and summarised in chronolog-
cal order in Tables 1–3.
nti-inﬂammatory and anti-oedematous activity
It has been conﬁrmed that aescin is mainly responsible for the
nti-inﬂammatory and anti-oedematous activity of the horse chest-
ut seed extract (Table 1). The research results have shown that
he complete extract has been around 100 times more effective as
he treatment for inﬂammation and lymphoedema in rats than the
xtract from which aescin was removed (Guillaume and Padioleau,
994).
The mechanism of the anti-inﬂammatory and anti-oedematous
ctivity of HCSE and aescin is multi-directional and has been pro-
osed on the basis of results of in vitro and in vivo studies (Fig. 1).
t was demonstrated that aescin counteracted ATP reduction and
n increase in the activity of phospholipase A2 responsible for the
elease of precursors of inﬂammatory mediators (Arnould et al.,
996; Sirtori, 2001). Moreover, aescin reduced neutrophil adhesion
nd aggregation, which was shown in ex vivo studies on an isolated
uman umbilical vein. Incubation thereof in hypoxic conditions in
n aescin solution or without it proved that aescin inhibited adhe-
ion of neutrophils to the vascular endothelium, activated them,
nd produced leukotriene B4 and the superoxide anion (Bougelet
t al., 1998). In an experimental model of rat pleurisy, HCSE reduced
lasma extravasation and leukocyte migration to the pleural cavity
s well as the release of inﬂammatory mediators, which resulted in
nhibition of inﬂammation and oedema (Guillaume and Padioleau,
994). In in vitro studies, the aescin restrained hyaluronidase activ-
ty by 93%, which resulted in inhibition of permeability and the
oss of plasma from the cells of vascular endothelium and, as a
onsequence, in a decrease in the occurrence of oedema (Facino
t al., 1995). In addition, aescin decreased the activity of lysosomal
nzymes, which shifted the proteoglican synthesis-breakdown bal-
nce towards synthesis thereof. In vivo studies showed that aescin
dministered intraperitoneally to rats for three weeks signiﬁcantly
educed degradation of mucopolysaccharides in the connective tis-
ue (the xiphoid process) (Panigati, 1992). Aescin and HCSE are also
haracterised by the antihistaminic and antiserotonin activity. It
as demonstrated that HCSE administered orally to rats dimin-
shed or inhibited excessive permeability of skin capillaries caused
y previous administration of histamine and serotonin (Guillaume
nd Padioleau, 1994). The later research proved that aescin Ib (2),
Ia (3), and IIb (4) had the antihistaminic and anti-serotonin activ-
ty while aescin Ia (1) mainly inhibited histamine (Matsuda et al.,
997). The anti-exudative activity of aescin is also connected with
elective sensitisation of vascular smooth muscles to Ca2+ ions,
hich leads to the increased tension and sealing thereof and, as
 result, to a decrease in the inﬂammation caused by vascular
ndothelium hypoxia. Results of in vitro studies conﬁrmed the
bove. Aescin caused concentration-dependent contraction rings
f inferior vena cava from male rats incubated in normal Krebs.
n Ca2+− free Krebs there was essentially no contraction to aescin,
ut in aescin-treated veins incubated in Ca2+ free Krebs, stepwise
ddition of extracellular CaCl2 caused corresponding increases in
ontraction (Raffetto and Khalil, 2011).
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demonstrated in models of inﬂammation that reproduce the ini-
tial exudative phases, such as oedema of laboratory animal paws
induced by a range of irritating agents (albumin from chicken egg
white (Girerg et al., 1961) dextran (Damas et al., 1976), cotton pel-
let, carrageenin (Cebo et al., 1976; Matsuda et al., 1997), bradykinin,
compound 48/80, chloroform (Matsuda et al., 1997)), in serous peri-
tonitis caused by injections of formalin in rats or carrageenin in
mice (Sirtori, 2001).
Effect on venous tension and blood ﬂow
The effectiveness of HCSE and aescin as the treatment for chronic
venous insufﬁciency is also connected with the inﬂuence on the
tension of veins (Table 2). As a result of an increase in the tension
of vein walls, the blood ﬂow through the vessels is accelerated and
venous outﬂow improves. The consequence is that venous blood
congestion decreases, which, in turn, enhances microcirculation as
erythrocyte dispersion increases and tissue oxygenation improves,
the ﬂow through vasa vasorum accelerates, the time of leukocyte
migration through the blood vessels and, therefore, the chance for
activation thereof initiating the cascade of an inﬂammatory reac-
tion is lowered.
It was shown that HCSE and aescin affected venous tension by
increasing production of prostaglandin F2 (PGF2), which partici-
pates in regulating the contractile action of veins, and inhibiting the
catabolism of venous tissue mucopolysaccharides (Sirtori, 2001).
The increased venous tension may  also be connected with the effect
of HCSE on serotonin 5-HT2A receptors, which was demonstrated
in in vitro studies on an isolated vein and artery. Their incubation
in HCSE caused a contraction, whereas in a simultaneously con-
ducted experiment their pre-incubation in a solution of ketanserin,
an antagonist for 5-HTA2 receptors, did not show any contraction
after HCSE. This proved that the contraction mechanism was con-
nected with stimulation of 5-HTA2 receptors (Felixsson et al., 2010).
The improvement of blood ﬂow in vessels by the extract from horse
chestnut seeds was also associated with its effect on blood rheology,
by decreasing viscosity in particular (Klemm,  1982). The inﬂuence
of aescin and HCSE on the increase in venous tension was  conﬁrmed
in in vitro studies on isolated veins of various animals and human
veins as well as in in vivo studies (Annoni et al., 1979; Felixsson
et al., 2010; Guillaume and Padioleau, 1994; Lochs et al., 1974).
Clinical studies
Evaluation of the effectiveness of HCSE-containing prepara-
tions was performed on patients with CVI; only two clinical trials
involved healthy volunteers (Table 3). These were randomised,
double-blind, placebo-controlled studies, part of which was  con-
ducted by the cross-over method where each patient took both
HCSE and the placebo in separate treatment cycles while the rest
were parallel studies in which patients were divided into two
groups – taking either HCSE or the placebo.
In the studies a daily dose of 600 mg  of HCSE (which corresponds
to 100 mg  of aescin/day) was  administered most frequently, mainly
in two  doses; the patients took the medicine for 2–16 weeks.
In the research carried out between 1976 and 1978, a 0–3 scale
was used to evaluate the degree of intensity of the complaints typ-
ical for CVI. A signiﬁcant reduction in the symptoms was  observed
in patients administered HCSE in comparison with those taking the
placebo (Friederich et al., 1978; Neiss and Böhm, 1976).In later years (1986–2002), water displacement plethysmom-
etry (Diehm et al., 1992; Lohr et al., 1986; Rudofsky et al., 1986;
Steiner and Hillemanns, 1990; Steiner, 1991) and measurement of
the ankle and calf circumference (Diehm et al., 1992; Lohr et al.,
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Table  1
Studies of anti-inﬂammatory and antioedema activity of HCSE and aescin.
Extracts/compounds Dose/route of administration Model/effect Authors
In vitro
Aescin 300 M Inhibition of activity of hyaluronidase by 93% (IC 50 = 150 mM),
respectively less at lower concentrations
Facino et al. (1995)
Aescin
(Reparil)
100–750 ng/ml Human umbilical vein endothelial cells activated by hypoxia,
inhibition of decrease in ATP content (EC50 = 260 ng/ml), inhibition
of  activation of phospholipase A2 (EC50 = 90 ng/ml), inhibition of
adhesion of neutrophils (EC50 = 90 ng/ml)
Arnould et al. (1996)
Aescin 10−9–10−4 M In rings of inferior vena cava from male rats segments incubated in
normal Krebs (2.5 mM Ca2+), aescin caused
concentration-dependent contraction (max 104.3 mg/mg  tissue at
10−4 M;  48.3% of control KCl contraction). In Ca2+ free Krebs, there
was  essentially no contraction to aescin. In aescin-treated veins
incubated in Ca2+ free Krebs, stepwise addition of extracellular
CaCl2 caused corresponding increases in contraction (max 80.0% of
control at 2.5 mM)
Raffetto and Khalil
(2011)
In vivo
Aescin i.v.;  0.2–2.5 mg/kg Reduction of oedema of rat paw induced by ovalbumin Girerg et al. (1961)
Aescin s.c.; 4 mg/kg Reduction of dextran induced rat paw oedema Damas et al. (1976)
Fraction of saponins i.v. – 3.75 mg/kg
p.o. – 7.5 mg/kg
Inhibition of hind rat paws inﬂammation induced by carrageenan,
analgesic activity
Cebo et al. (1976)
Aescin
(Reparil i.v.  form)
(ex vivo)
250 ng/ml (0.22 M)  Inhibition of neutrophil adhesion to hypoxic endothelium,
activation and release of free radicals
Bougelet et al. (1998)
Aescin i.p.; 1 mg/kg/day (3 weeks) Reduction of degradation of mucopolysaccharides in rat
connective tissues (xiphoid cartilage); studies of
sulphomucopolysaccharides marked S35
Panigati (1992)
HCSE
(70% aescin)
(Veinotonyl 75)
p.o.; 200–400 mg/kg
i.v.; 1–10 mg/kg
Lymphatic oedema in rats; reduction of plasmatic extravasation,
leukocytes migration, release of inﬂammatory mediators, leading
to inhibition of inﬂammation
Guillaume and
Padioleau (1994)
p.o.; 50–300 mg/kg
i.v.;  2.5–5 mg/kg
Reduction of capillary hyperpermeability induced by chloroform in
rabbits
p.o.;  150–400 mg/kg
(60 min  before the
administration of histamine
and serotonin)
Reduction of capillary hyperpermeability induced by serotonin or
histamine in rats (maximum effect at a dose of 200 mg/kg)
p.o.;  50–400 mg/kg Increase in skin capillary resistance in guinea pigs fed a
scorbutogenic diet for 3 weeks
Aescins Ia (1), Ib
(2), IIa and IIb
p.o.; 50–200 mg/kg Dose-dependent inhibition of increased vascular permeability
induced by subcutaneous administration of acetic acid to mice,
and histamine (aescin Ia, Ib, IIa, IIb) and serotonin (aescin Ib, IIa,
IIb) to rats
Matsuda et al. (1997)
Inhibition of hind paw oedema induced by carrageenin at ﬁrst
phase in rats (aescin Ia, Ib, IIa and IIb)
Dose-dependent inhibition of scratching behaviour induced by
subcutaneous injection of compound 48/80 in mice (aescin Ib, IIa
and  IIb, aescin Ia – the weakest activity, only at a maximum dose)
Table 2
Studies of venotonic activity of HCSE and aescin.
Extracts/compounds Dose/route of
administration
Model/effect/route of application Authors
In vitro
HCSE
Aescin
0.2 mg/ml
0.1 mg/ml
Increased tension of cow vein and human saphenous
vein incubated in tested solutions, the effect lasted for
3 h
Lochs et al. (1974)
Aescin 1 ng/ml–1 mg/ml  Increased tension of human saphenous vein incubated
in tested solutions, the pharmacological effect
comparable to serotonin and dihydroergotamine,
signiﬁcantly stronger than acetylcholine and
vasopressin
Annoni et al. (1979)
HCSE
(70% aescin)
0.05–0.5 mg/ml
(0.5–5 × 10−4)
Increased tension of dog saphenous vein incubated in
tested solutions
Guillaume and
Padioleau (1994)
25–50 mg  Increased tension of perfused dog saphenous vein
HCSE 1  mg/ml Inhibition of aggregation of ADP-induced human
platelets
Felixsson et al. (2010)
0.1–10 mg/ml Contraction of isolated vein and artery incubated in
HCSE solution, previous incubation in ketanserin
solution (10−6 and 10−5 M)  resulted in inhibition of
contraction after HCSE
In  vivo
HCSE
(70% aescin)
i.v.; 50 mg  Increased venous pressure, venous and lymphatic
ﬂows in femoral dog vein
Guillaume and
Padioleau (1994)
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Table  3
Clinical trials of efﬁcacy of HSCE in CVI.
Daily dose
Preparation
Duration Design of
study, number
of patients
Indications Improvement of signs and symptoms Authors
HCSE – internal use
300 mg  HCSE caps.a
2×/day
(brand not stated)
20 days R, DB, PC, PG,
CO
n  = 226
CVI, varicosis Signiﬁcant alleviation (p < 0.05) of leg
pain, oedema and pruritus in
participants treated with HCSE
compared to placebo
Neiss and
Böhm (1976)
300 mg  HCSE caps.a
2×/day
(brand not stated)
20 days R, DB, PC, CO
n  = 95
CVI, varicosis Signiﬁcant reduction (p < 0.05) of calf
spasm, pain, fatigue, and tenseness
compared to placebo
Friederich et al.
(1978)
300 mg  HCSE caps.a
2×/day
Venostasin® Retard
8 weeks R, DB, PC, PG
n  = 74
CVI Reduction of leg volume of 16.5 ml
compared to 3.8 ml  reduction with
placebo, reduction of formation of
oedema (21.0 ml) with HCSE and
increase (0.2 ml) with placebo during
oedema-provoking period
Lohr et al.
(1986)
2 × 300 mg HCSE
caps.a 1×/day
Venostasin® Retard
4 weeks R, DB, PC, CO
n  = 22
CVI Signiﬁcant reductions (p < 0.01) of
capillary ﬁltration coefﬁcient by 22%
compared to placebo
Bisler et al.
(1986)
300 mg  HCSE caps.a
2×/day
(brand not stated)
4 weeks R, DB, PC, PG
n  = 39
CVI grade I or II Signiﬁcant reduction (p < 0.001) in leg
volume (78 ml) compared to increase
with placebo (34 ml), signiﬁcant
reduction (p < 0.01) in calf and foot
circumference, signiﬁcant reduction in
subjective parameters (pain, tiredness,
tension, and pruritus in legs) compared
to  placebo
Rudofsky et al.
(1986)
300 mg  HCSE caps.a
2×/day
(brand not stated)
20 days R, DB, PC, PG
n  = 28
CVI Signiﬁcant reduction (p < 0.05) of
0.8 cm in leg circumference and
oedema at ankle compared with
placebo, alleviation of subjective
symptoms (p < 0.05)
Pilz (1990)
300 mg  HCSE caps.a
2×/day
Venostasin® Retard
20 days R, DB, PC, CO
n  = 52
Pregnant
women  with
oedema due to
CVI
Signiﬁcant reduction (p < 0.01) in foot
volume before and after oedema
provocation and greater resistance to
oedema provocation compared to
placebo,  reduction in foot
circumference and subjective
symptoms compared to placebo
Steiner and
Hillemanns
(1990)
300 mg  HCSE caps.a
2×/day
Venostasin® Retard
2 weeks R, DB, PC, CO
n  = 20
CVI, varicosis
during
pregnancy
Signiﬁcant reduction (p = 0.009) in leg
volume (114 ml in patients with
varicose veins and 126 ml  in patients
with CVI) and subjective symptoms
(p < 0.05) compared to placebo
Steiner (1991)
300 mg  HCSE caps.b
2×/day
(brand not stated)
6 weeks R, DB, PC, PG
n  = 39
Venous
oedema in
chronic deep
vein
incompetence
(CVI grade II)
Signiﬁcant reduction (p < 0.01) in leg
volume by an average of 84 ml
compared with baseline, while
reduction of 4 ml  with placebo,
alleviation of subjective symptoms
(feelings of heaviness, tension, fatigue,
and paresthesia) in legs, itching not
helped
Diehm et al.
(1992)
HCSE – external use
Esseven gel 4 weeks R
n = 30
SVT Alleviation of subjective symptoms,
decrease in body temperature
De Sanctis et al.
(2001)
Esseven gel
1×/day
4 weeks R
n = 22
CVI, acute
lower leg
ulcers
Improved blood ﬂow parameters and
microcirculation, alleviation of
subjective symptoms
Cesarone et al.
(2001a)
Esseven gel 4 weeks R, DB
n = 15
Foot ulcers as a
result of
diabetes
complications
Improvement of microcirculation,
reduction of skin ulcers
Cesarone et al.
(2001b) and
Incandela et al.
(2001)
HCSE vs. reference medications
300 mg  HCSE caps.a
2×/day
vs. reference
medication
(probably rutosides,
brand not stated)
4 weeks R, DB, PG, Cm
n = 30
CVI Signiﬁcantly reduced (p value not
reported) ankle circumference by
0.4 cm and improved subjective
symptoms compared with baseline,
ankle circumference reduced by 0.4 cm
(rutosides)
Erdlen (1989)
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Table  3 (Continued )
Daily dose
Preparation
Duration Design of
study, number
of patients
Indications Improvement of signs and symptoms Authors
300 mg  HCSE caps.a
1×/day
vs. 500 mg  HRc
1×/day
(brand not stated)
8 weeks R, DB, PG, Cm
n  = 30
CVI Ankle and calf circumference reduced
by 0.2 and 0.18 cm,  respectively,
compared to baseline, values not
signiﬁcantly different compared with
HR
Kalbﬂeisch and
Pfalzgraf
(1989)
300 mg  HCSE caps.b
2×/day
vs.2000 mg  HRc
1×/day
8 weeks R, DB, PG, Cm
n  = 40
CVI and
peripheral
venous oedema
HCSE signiﬁcantly protected calf and
ankle from oedema provocation
compared with baseline, both HCSE
and HR comparable in reducing
oedema, more pronounced protective
effect of HCSE
Erler (1991)
300 mg  HCSE caps.a
2×/day
vs. 1000 mg  HR3/day
(4 weeks)
500 mg  HR3/day (4
weeks)
(brand not stated)
12 weeks R, DB, PG, MC,
Cm
n  = 137
Postmenopausal
CVI grade II
Signiﬁcant reduction (p value not
reported) in leg volume of 28 ml
(HCSE), 58 ml (HR 1000 mg/day) and
40 ml  (HR 1000 mg/day for 4 weeks
then 500 mg/day for 8 weeks)
compared to baseline, alleviated
subjective symptoms, after 6-week
follow-up period both treatments
exhibited substantial carry-over effect
Rehn et al.
(1996)
300 mg  HCSE caps.a
2×/day
(Venostasin® Retard)
vs. mechanical
compression with
bandages and class II
elastic stocking
12 weeks R, SB, PC, PG,
Cm
n = 240
CVI Signiﬁcant reduction in leg volume of
43.8 ml  (HCSE), 46.7 ml (compression
therapy) and increase -9.8 ml (placebo)
(HCSE and compression therapy vs.
placebo p = 0.005), HCSE compared
with compression therapy p = 0.001),
HSCE was  well-tolerated (98%
compliance), whereas compression
treatment was reported as
uncomfortable, inconvenient and
subject to poor (90%) compliance
Diehm et al.
(1996)
300 mg  HCSE caps.a
2×/day
(Venostasin® Retard)
vs. mechanical
compression with
bandages and class II
elastic stocking
16 weeks R, DB, PC, PG,
Cm
n  = 286
CVI grade II and
IIIa
Reduction of lower leg volume during
treatment in both therapy groups,
whereas in placebo group, there were
no effects
Diehm and
Schmidt (2001)
300 mg  HCSE caps.
2×/day
(Venostasin® Retard)
vs. 360 mg
Pycnogenol/day
4 weeks R, PG, O, Cm
n = 40
CVI Pycnogenol: signiﬁcant reduction of
circumference of lower limbs,
signiﬁcantly improved subjective
symptoms of pain, cramps, night-time
swelling, feeling of ‘heaviness’, and
reddening of skin, decrease in
cholesterol and LDL values in blood,
whereas HDL remained unaffected,
Venostasin: insigniﬁcant reduction of
circumference of lower limbs,
marginally improved symptoms, no
inﬂuence on the determined lipid
values, both medications were equally
well tolerated
Koch (2002)
Essaven gel: Hippocastani seminis extractum spissum, 83.5 mg/g aescin; Hyperianum natricum, 0.42 mg/g.
CVI, chronic venous insufﬁciency; Cm,  comparison; CO, cross-over; DB, double-blind; MC, multicentre; O, open; PC, placebo-controlled; PG, parallel group; R, randomised;
SB,  single blind.
a HCSE capsules standardised to 50 mg  aescin each.
b HCSE capsules standardised to 75 mg  aescin each.
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986; Pilz, 1990) were additionally applied to measure the effec-
iveness of HCSE-containing preparations.
The research involved people with diagnosed CVI, varicose
eins, including those developed during pregnancy. It was shown
hat the leg volume considerably decreased in the groups taking
CSE, whereas in the patients administered the placebo it lowered
nly slightly or not at all (Diehm et al., 1992; Lohr et al., 1986;
udofsky et al., 1986; Steiner and Hillemanns, 1990). Alleviation of
he subjective complaints and an improvement in the general phys-
cal activity was observed in the patients taking HCSE, in contrast
o those taking the placebo.The effect of HCSE on capillary ﬁltration and the intravascular
volume of the lower limb vein were also assessed in patients with
CVI. Three hours after administration of the preparation, the cap-
illary ﬁltration increased insigniﬁcantly in the patients taking the
placebo while in those taking HCSE it decreased. A decrease in the
intravascular volume (−5%) was  not considerable, which proved
that the effectiveness of HCSE resulted from the impact on the abil-
ity to reduce capillary permeability to a larger extent than from the
inﬂuence on the vein tension (Bisler et al., 1986).
Moreover, the studies comparing the effectiveness and safety
of use of HCSE therapy and compression therapy were conducted.
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sing both class II elastic stockings and HCSE caused a signiﬁcant
ecrease in leg volume while in the case of the placebo leg volume
lightly increased. HCSE and compression therapy were both well
olerated and no serious complications were reported. The results
uggested that use of elastic stockings as well as HCSE ensured sim-
lar effectiveness in treating patients with oedema caused by CVI
Diehm et al., 1996; Diehm and Schmidt, 2001).
The research that aimed at a comparison of the effectiveness of
CSE with that of O-(-hydroxyethyl)-rutosides (HR) was done,
oo. HR showed similar effectiveness to HCSE (reduction in the
nkle and calf circumference, a leg volume reduction) (Erdlen,
989; Erler, 1991; Kalbﬂeisch and Pfalzgraf, 1989; Rehn et al.,
996). In the other studies, the efﬁcacy of HCSE and pycnogenol
as compared. Pycnogenol signiﬁcantly reduced the circumference
f the lower limbs, improved subjective symptoms and decreased
holesterol, and LDL values in the blood, whereas HDL remained
naffected. HCSE only moderately but not signiﬁcantly reduced the
ircumference of the lower limbs, marginally improved symptoms
nd had no inﬂuence on the determined lipid values. Pycnogenol
as found to be more efﬁcacious than HCSE for the treatment of
VI (Koch, 2002).
The effectiveness of local application of a preparation containing
CSE with an addition of heparin (Essaven gel) was  also evaluated.
lleviation of the symptoms and a fall of skin temperature were
bserved in patients with superﬁcial vein thrombosis (SVT) (De
anctis et al., 2001) while in those with CVI and acute lower leg
lcers a signiﬁcant improvement in the blood ﬂow and microcir-
ulation parameters was  found (Cesarone et al., 2001a). Improved
icrocirculation and a considerable decrease in skin ulcers within
he foot were also observed after application of this preparation in
iabetics (Cesarone et al., 2001b; Incandela et al., 2001).
The effect of HCSE on pedal oedema in people travelling on long-
aul ﬂights was assessed (n = 19; double-blind trials). The results
emonstrated lesser foot oedema in people prophylactically taking
00 mg  of HCSE before the ﬂight (Marshall and Dormandy, 1987).
ther studies on healthy volunteers (n = 12; double-blind, placebo-
ontrolled trial) showed that standardised HCSE administered once
t a dose of 600 mg  decreased vascular volume and the capillary
ltration rate (Pauschinger, 1987).
harmacokinetics
A few of the reports on the pharmacokinetic and pharma-
oavailability of aescin were published. The conducted studies
llowed to compare the bioavailability of aescin (50 mg  contained
n 240–290 mg  of HCSE) in a prolonged release formulation and
ther pharmaceutical formulations after oral administration. In a
ingle dose experiment Cmax was 3.2–9.8 ng/ml while in a repeated
ose experiment Cmax was 6.5–16.7 ng/ml. In both of the discussed
linical studies the differences in the concentrations of aescin in the
lood/plasma were observed (Loew et al., 2000).
Furthermore, after oral administration of an aescin solution, the
bsolute bioavailability was low and determined as only 1.5%. This
act was probably due to the ﬁrst pass effect (metabolism and bil-
ary excretion). The relative bioavailability of aescin from a HCSE
Venostasin retard®) was 100% compared to an aescin solution
EMEA, 2012).
The pharmacokinetics of aescin, after intravenous administra-
ion, corresponded to an open three compartment model. The
liminations half-times of 5 mg  aescin (infusion rate: 718 g/min)
ere: t0.5 – 6.6 min; t0.5 – 1.74 h and t0.5 – 14.36 h. Moreover,
he distribution volume was 100.9 l, binding to plasma proteins
as 84%, total plasma and renal clearances were 21.8 ml/min and
.7 ml/min respectively. Following 120 h after the dose administra-
ion, aescin excreted in the urine (EMEA, 2012).sileira de Farmacognosia 25 (2015) 533–541 539
Side-effects, toxicity
Preclinical data
Weak genotoxic activity of a commercial dry extract as well
as ﬂuid extracts of horse chestnut seeds was demonstrated in the
Ames test on strains of Salmonella typhimurium TA 98 (EMEA, 2012;
ESCOP, 2003).
HCSE studies on rats and rabbits (100 and 300 mg/kg bw)
showed no teratogenic activity. A fall in the average body
weight of the foetus was only observed after application of
large doses of HCSE. HCSE single dose toxicity studies (Venos-
tatin retard® preparation, standardised for the content of 50 mg
of aescin in 240–290 mg  extract) conducted on animals (mice,
rats, guinea pigs, and rabbits) demonstrated greater toxicity
of the extract when administered intravenously and intraperi-
toneally (LD50 6.8–465 mg/kg bw) than after oral administration
(LD50 910–2600 mg/kg bw). The LD50 values ranged from 3 to
17 mg/kg bw after intravenous and intraperitoneal administration
of aescin to laboratory animals (EMEA, 2012).
The studies of chronic oral toxicity of HCSE were carried out on
dogs (20, 40, 80 mg/kg bw;  5 days/week/3 month) and rats (100,
200, 400 mg/kg bw;  5 days/week/3 month). The obtained results
proved a lack of toxicity of the administered extract.
In the study of sub-acute intravenous toxicity, HCSE was  admin-
istered to rats at doses of 9, 30, 90 mg/kg/day for 60 days. The dose
of 90 mg/kg caused death of 8 out of 30 animals as early as in the
ﬁrst days of the study; the doses of 30 and 9 mg/kg did not lead to
any signiﬁcant disorders and were safe for the animals (Liehn et al.,
1972).
Aescin, at a dose of 2 × 50 mg/kg bw, given to young, 32-day old
rats, did not affect fertility, and nephrotoxicity was  not detected
either (EMEA, 2012).
A lack of the nephrotoxic properties of aescin was  also conﬁrmed
in a study on the inﬂuence of free and albumin-bound aescin on
renal tubular transport performed on an isolated, artiﬁcially per-
fused frog kidney. It was  proven that the low harmfulness resulted
from the ability of aescin to bind with plasma proteins (50%), and
the concentration of free aescin ﬁltered through the kidney was
considered too low to be able to have a toxic effect (Barnes et al.,
2007).
Clinical data
The results of three clinical studies proved a lack of toxic effects
of HCSE and aescin on the renal function after i.v. administration.
The studies involved healthy volunteers or patients with impaired
renal function, both adults and children. The kidney function was
monitored every day; BUN, serum creatinine and creatinine clear-
ance were determined, and the urine analysis was  performed. It
was shown that aescin did not cause decreased kidney efﬁciency in
the individuals from the examined groups (EMEA, 2012).
The research showed that use of HCSE was  safe. Ailments
connected with HCSE application were transient and of little inten-
sity; gastrointestinal disorders, dizziness, headaches, and itch were
observed (Barnes et al., 2007; Diehm et al., 1996; EMEA, 2012; Neiss
and Böhm, 1976; Rehn et al., 1996; Steiner and Hillemanns, 1990).
Contra-indications, warnings
The safety of use of the horse chestnut seed extract during
pregnancy and lactation has not been deeply investigated. The
results of the only study conducted so far with the participation of
pregnant women showed that use of HCSE did not cause any unde-
sirable activity (Steiner, 1991; EMEA, 2012). However, use of the
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harmacologically active constituents of A. hippocastanum should
e avoided during pregnancy and lactation (Barnes et al., 2007).
Despite the literature data describing interactions between
reparations containing HCSE and other medicinal agents, applica-
ion of the extract simultaneously with other medicines, especially
hose of similar or opposite activity, requires caution. It was also
hown that aescin bound with plasma proteins; however, the inﬂu-
nce on binding of other drugs or a lack thereof was not conﬁrmed
Barnes et al., 2007; EMEA, 2012).
There is no information about overdose, drug abuse, withdrawal,
nd rebound effect or the impact on the ability to drive or operate
achinery or impairment of mental ability.
onclusions
CVI is a common disorder of venous vessels affecting mainly the
lderly. Preparations containing HCSE/aescin have long been used
o alleviate both the subjective symptoms, such as the feeling of
iredness, itching, cramps, paresthesia, and the objective ones, i.e.
ecreased leg volume. HCSE standardised for the content of aescin
r aescin isolated from the extract are used. -Aescin is industrially
btained in the amorphous form, which is characterised by bet-
er bioavailability due to better solubility. Most frequently, 600 mg
f HCSE, which corresponds to 100 mg  of aescin, is applied daily.
andomised clinical studies showed beneﬁcial effects of such a
reatment after 2–16 weeks, and its effectiveness was similar to that
f compression therapy or administration of hydroethylrutoside or
ycnogenol.
The activity of HCSE is mainly connected with the presence
f aescin, which is the major active compound of the extract.
umerous in vitro and in vivo studies enabled to investigate the
echanism of HCSE/aescin activity, which is mainly connected
ith anti-oedema, anti-inﬂammatory, vessel protective, and the
enotonic activity.
Moreover, preparations containing HCSE/aescin have been
roven to be safe. Over 40 years of research into the undesirable
ffects of the horse-chestnut seed extract applied internally have
roved very good tolerance thereof, and the sporadic ailments,
ainly gastrointestinal disorders, have been transient.
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